drugset / Trial / NCT00671619
Study of ESBA105 Eye Drops in Healthy Subjects
RandomizedSingle-groupDouble-blindTreatment
Summary
Objectives: To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically to the eye for up to 28 days in healthy volunteers. To determine the systemic exposure to ESBA105 upon single and repeated-dose topical application to the eye in healthy volunteers.
Timeline
- Start
- 2008-04
- Primary completion
- 2008-07
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ESBA105 | Monoclonal antibody | — | Topical |
Indications
No indication recorded.